Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Circassia Pharmaceuticals ( (GB:NIOX) ) has issued an update.
NIOX Group plc, a company listed on the AIM market, has announced its total voting rights as of September 30, 2025. The company’s issued share capital consists of 417,871,617 ordinary shares, each carrying one voting right, with no shares held in treasury. Recently, employees exercised options over 45,432 ordinary shares under the company’s share option schemes. The admission of these new shares has been satisfied via block listing and will rank equally with existing shares. This information is crucial for shareholders to determine their notification requirements under the FCA’s Disclosure and Transparency Rules.
The most recent analyst rating on (GB:NIOX) stock is a Hold with a £76.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.
Spark’s Take on GB:NIOX Stock
According to Spark, TipRanks’ AI Analyst, GB:NIOX is a Neutral.
Circassia Pharmaceuticals’ overall stock score is driven primarily by its strong financial performance, characterized by robust revenue growth and cash flow management. The technical analysis indicates a positive trend, though momentum is limited. The high P/E ratio suggests potential overvaluation, partially offset by a decent dividend yield.
To see Spark’s full report on GB:NIOX stock, click here.
More about Circassia Pharmaceuticals
Average Trading Volume: 849,444
Technical Sentiment Signal: Buy
Current Market Cap: £306.7M
For detailed information about NIOX stock, go to TipRanks’ Stock Analysis page.